C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2041

Conditions
Diffuse Intrinsic Pontine GliomaHigh Grade GliomaEmbryonal TumorEpendymal Tumor
Interventions
GENETIC

C7R-GD2.CART cells (IV and ICV infusion)

"Dose levels administered are by IV infusion followed by ICV infusion.~Cycle 1: 10 million cells/m2 delivered IV with lymphodepletion.~Cycle 2 (and subsequent cycles):~Dose level 1: 2 million cells ICV with lymphodepletion. Dose level 2: 5 million cells ICV with lymphodepletion."

GENETIC

C7R-GD2.CAR T cells (IV infusion)

Dose levels administered are by IV infusion. For all cycles, the dose level is 10 million cells/m2 IV with lymphodepletion.

Trial Locations (1)

77030

RECRUITING

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Faris Foundation

UNKNOWN

collaborator

ChadTough Defeat DIPG Foundation

UNKNOWN

collaborator

Violet Foundation for Pediatric Brain Cancer

UNKNOWN

lead

Baylor College of Medicine

OTHER